Skip to main content
Press release September 22, 2026

IN8bio to Present at Sidoti Small-Cap Virtual Conference

In8bio, Inc. (INAB)

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and
View original release